Literature DB >> 21430056

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Delphine C Malherbe1, Nicole A Doria-Rose, Lynda Misher, Travis Beckett, Wendy Blay Puryear, Jason T Schuman, Zane Kraft, Jean O'Malley, Motomi Mori, Indresh Srivastava, Susan Barnett, Leonidas Stamatatos, Nancy L Haigwood.   

Abstract

A major goal of human immunodeficiency virus type 1 (HIV-1) vaccine efforts is the design of Envelope (Env)-based immunogens effective at eliciting heterologous or broad neutralizing antibodies (NAbs). We hypothesized that programming the B-cell response could be achieved by sequentially exposing the host to a collection of env variants representing the viral quasispecies members isolated from an individual that developed broad NAbs over time. This ordered vaccine approach (sequential) was compared to exposure to a cocktail of env clones (mixture) and to a single env variant (clonal). The three strategies induced comparable levels of the autologous and heterologous neutralization of tier 1 pseudoviruses. Sequential and mixture exposure to quasispecies led to epitope targeting similar to that observed in the simian-human immunodeficiency virus (SHIV)-infected animal from which the env variants were cloned, while clonal and sequential exposure led to greater antibody maturation than the mixture. Therefore, the sequential vaccine approach best replicated the features of the NAb response observed in that animal. This study is the first to explore the use of a collection of HIV-1 env quasispecies variants as immunogens and to present evidence that it is possible to educate the B-cell response by sequential exposure to native HIV-1 quasispecies env variants derived from an individual with a broadened NAb response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430056      PMCID: PMC3094990          DOI: 10.1128/JVI.02419-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Evolutionary and immunological implications of contemporary HIV-1 variation.

Authors:  B Korber; B Gaschen; K Yusim; R Thakallapally; C Kesmir; V Detours
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

3.  Overcoming original (antigenic) sin.

Authors:  D E Anderson; M P Carlos; L Nguyen; J V Torres
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

4.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.

Authors:  R A Rasmussen; D C Montefiori; H L Robinson; H M McClure; R M Ruprecht
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

7.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Nancy Haigwood; Reza Sadjadpour; Ron J Plishka; Alicia Buckler-White; Riri Shibata; Malcolm A Martin
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Authors:  Penny L Moore; Emma T Crooks; Lauren Porter; Ping Zhu; Charmagne S Cayanan; Henry Grise; Paul Corcoran; Michael B Zwick; Michael Franti; Lynn Morris; Kenneth H Roux; Dennis R Burton; James M Binley
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more
  64 in total

Review 1.  Prospects for an HIV vaccine: leading B cells down the right path.

Authors:  Susan Moir; Angela Malaspina; Anthony S Fauci
Journal:  Nat Struct Mol Biol       Date:  2011-12-05       Impact factor: 15.369

Review 2.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

4.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.

Authors:  Jue Hou; Shubham Shrivastava; Hooi Linn Loo; Lan Hiong Wong; Eng Eong Ooi; Jianzhu Chen
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

5.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

6.  SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Andrea Kirmaier; Sivan Leviyang; Celia LaBranche; Jinghe Huang; Sonya Whitted; Kenta Matsuda; David Montefiori; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

7.  HIV vaccine trial exploits a dual and central role for innate immunity.

Authors:  Deborah Heydenburg Fuller; Laura E Richert-Spuhler; Nichole R Klatt
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

8.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

9.  Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.

Authors:  Ebony Gary; Margaret O'Connor; Marita Chakhtoura; Virginie Tardif; Ogan K Kumova; Delphine C Malherbe; William F Sutton; Nancy L Haigwood; Michele A Kutzler; Elias K Haddad
Journal:  Vaccine       Date:  2020-04-10       Impact factor: 3.641

Review 10.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.